Abstract
Pain can have a significantly negative impact on the quality of life of patients. Therefore, patients may resort to analgesics to relieve the pain. The struggle to manage pain in cancer patients effectively and safely has long been an issue in medicine. Analgesics are the mainstay treatment for pain management as they act through various methods on the peripheral and central pain pathways. However, the variability in the patient genotypes may influence a drug response and adverse drug effects that follow through. This review summarizes the observed effects of analgesics on UDP-glucuronosyl (UGT) 2B7 isoenzyme, cytochrome P450 (CYP) 2D6, μ-opioid receptor μ 1 (OPRM1), efflux transporter P-glycoprotein (P-gp) and ATP-binding cassette B1 ABCB1/multiple drug resistance 1 (MDR1) polymorphisms on the mechanism of action of these drugs in managing pain in cancer. Furthermore, this review article also discusses the responses and adverse effects caused by analgesic drugs in cancer pain management, due to the inter-individual variability in their genomes.
Reference114 articles.
1. Current aproach to cancer pain management: Availability and implications of different treatment options;Nersesyan;Ther. Clin. Risk Manag.,2007
2. Interventional Techniques for the Management of Cancer-Related Pain: Clinical and Critical Aspects
3. Clinical Implications of Opioid Pharmacogenomics in Patients with Cancer
4. Cancer Pain Relief and Palliative Care: Report of a WHO Expert Committee [Meeting Held in Geneva from 3 to 10 July 1989],1990
5. Morphine and alternative opioids in cancer pain: the EAPC recommendations
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献